Biogen gets regulators to accept NDA, MAA for BG-12; FDA green lights stem cell study in ALS;

 @FierceBiotech: First "cross-kingdom" vaccine effective in Phase I. Report | Follow @FierceBiotech

 @RyanMFierce: Check out Mark Leuchtenberger's scheduled IPO for Rib-X, an antibiotics developer, after price cut. More | Follow @RyanMFierce

> The FDA and EMA have accepted Biogen Idec's ($BIIB) applications for multiple sclerosis pill BG-12. The FDA granted a standard review for the drug, which Biogen aims to launch on the U.S. market next year. Item

> U.S. regulators have given a green light for three patients with ALS to receive a second dose of stem cells after the first dose was given to patients safely. Release

> Pulmotect has pulled in a $7.1 million grant from the Cancer Prevention & Research Institute of Texas to study a product for protecting patients on chemotherapy from infections. Announcement

Pharma News

 @FiercePharma: Here's Glaxo's take on the official launch of hostile HGS bid. More | Follow @FiercePharma

> DSM panel holds firm on new autism diagnosis, ditches 2 other revisions. News

> With generics horde advancing, Pfizer gives up Lipitor push. Report

> Roche's Tarceva wins NICE nod for first-line use. Article

> Glaxo can nail HGS buy with slightly bigger bid, analysts say. Item

Medical Devices News

 @FierceMedDev: Finland's ArcDia grabs $3.5M in new financing to fuel growth of its respiratory infection diagnostic test. Item | Follow @FierceMedDev

> FDA looks to reduce kids' radiation exposure in draft guidance. News

> George Will jumps on the anti-device tax bandwagon. Article

> Report: Bad lifestyles fuel diagnostics boom in emerging markets. Story

> Study: Worriers, negative folks fair worse with ICDs. Report

CRO News

 @NesaNFierce: Monkey see, monkey ... don't. MPI Research is getting lots of flack from the USDA and an animal rights group over animal mistreatment. Article | Follow @NesaNFierce

> CMO service pacts needed for success, Baxter says. News

> Kythera seeks $250,000 from Cetero for development delays. Story

> AMRI sees Q1 drops, but maintains positive financial outlook for 2012. More

> Covance sees early development losses, closes Arizona lab. Item

Pharma Manufacturing News

 @EricPFierce: Ranbaxy's stellar first quarter shows the upside of having pharma manufacturing operations tip top. Report | Follow @EricPFierce

> 12-year-old consent decree lifted from Abbott. Story

> FDA critical of Genentech's Avastin production. Article

> Pfizer may announce $129M expansion in Belgium. More

> Patheon exiting most manufacturing at U.K. plant. Item

Vaccines News

> MMR and autism: Italy's courts get involved. Report

> Study: Further insight into Merck HIV vax infection increase. Article

> Pneumococcal vax cuts deaths, but cases tripled. News

> Swine flu vax could offer universal flu protection. Story

And Finally… A cell therapy reversed Type 1 diabetes in a mouse study, giving researchers hope for a cure in humans. Item

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.